Executive Summary
Lockheed Martin secured a $74M NASA contract for the GEOXO Lightning Mapper with $371M total potential value over 25 years to 2049, providing long-term space R&D revenue visibility. This single award signals bullish momentum for LMT in NASA's geostationary satellite instrumentation push. Investors should monitor option exercises amid execution risks from the extended timeline.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior NASA & Space Contracts Intelligence digest from February 20, 2026.
Investment Signals (1)
- Lockheed Martin GEOXO Lightning Mapper Contract (HIGH)▲
25-year NASA contract with $74M obligation and $371M potential value locks in space R&D revenue through 2049.
Risk Flags (2)
- Execution [HIGH RISK]▼
25-year performance period to 2049 introduces funding and execution uncertainty over decades.
- Market [MEDIUM RISK]▼
Subawards of $2.36M could pressure margins if subcontractor costs rise.
Opportunities (2)
- ◆
Unobligated options could add ~$297M beyond current $74M obligation.
- ◆
Long-term NASA commitment to GEOXO Lightning Mapper supports sustained space R&D revenue.
Sector Themes (1)
- ◆
Single major award highlights NASA's focus on geostationary weather satellite tech via long-duration contracts.
Watch List (2)
- 👁
{"entity"=>"Lockheed Martin Space Segment", "reason"=>"Dominates this period's NASA awards with high-value, long-term potential.", "trigger"=>"Option exercises exceeding $100M or GEOXO delays"}
- 👁
{"entity"=>"NASA GEOXO Program Funding", "reason"=>"Critical to unlocking $297M in LMT options through 2049.", "trigger"=>"Budget shifts or congressional appropriations changes"}
Get daily alerts with 1 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: NASA & Space Contracts Intelligence
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals